GFM
ADPT icon

GF Fund Management’s Adaptive Biotechnologies ADPT Stock Holding History

GF Fund Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$69.9K Sell
3,260
-170
-5% -$2.6K ﹤0.01% 360
2026
Q1 		$47.6K Buy
3,430
+432
+14% +$6.88K ﹤0.01% 407
2025
Q4 		$48.7K Sell
2,998
-278
-8% -$4.54K ﹤0.01% 408
2025
Q3 		$49K Sell
3,276
-503
-13% -$6.13K ﹤0.01% 397
2025
Q2 		$44K Hold
3,779
– – ﹤0.01% 429
2025
Q1 		$28.1K Buy
3,779
+680
+22% +$5.23K ﹤0.01% 467
2024
Q4 		$18.6K Buy
+3,099
New +$17.1K ﹤0.01% 478

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

GF Fund Management's ADPT Position: Q2 2026 in Review

GF Fund Management reduced its Adaptive Biotechnologies (ADPT) stake by 5% in Q2 2026, selling an estimated $2.6K and leaving 3,260 shares worth $69.9K. The position accounts for ﹤0.01% of the portfolio, ranked #360.

GF Fund Management first reported a position in ADPT in Q4 2024 and has held it in 7 quarters since. 301 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

  • GF Fund Management held 3,260 shares of Adaptive Biotechnologies worth $69.9K as of Q2 2026.
  • GF Fund Management sold 170 Adaptive Biotechnologies shares in Q2 2026, an estimated $2.6K.
  • Adaptive Biotechnologies made up ﹤0.01% of GF Fund Management's portfolio in Q2 2026, its #360 holding.
  • GF Fund Management first reported a position in Adaptive Biotechnologies in Q4 2024 and has held it in 7 quarters since.
  • 301 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on GF Fund Management's 13F filing for Q2 2026, filed 7 Aug 2026.